Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.contraception.2004.07.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.
J Natl Cancer Inst
January 2025
School of Public Health, University of Queensland, Brisbane, QLD 4006, Australia.
Background: Use of long-acting, reversible contraceptives has increased over the past 20 years, but an understanding of how they could influence cancer risk is limited.
Methods: We conducted a nested case-control study among a national cohort of Australian women (n = 176 601 diagnosed with cancer between 2004 and 2013; 882 999 matched control individuals) to investigate the associations between the levonorgestrel intrauterine system, etonogestrel implants, depot-medroxyprogesterone acetate and cancer risk and compared these results with the oral contraceptive pill. We used conditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI).
Pharmacovigilance study of the association between progestogen and depression based on the FDA adverse event reporting System (FAERS).
Sci Rep
January 2025
Department of pharmacy, Heze University, Heze, 274000, Shandong Province, China.
Progestogens commonly used in the clinic include levonorgestrel, etonogestrel, medroxyprogesterone, hydroxyprogesterone, progesterone, desogestrel, and megestrol. Progestogens are widely used for contraception and the treatment of endometriosis, threatened abortion and other diseases. However, the correlation between progestogen use and depression is not clear.
View Article and Find Full Text PDFA low-cost and high-fidelity animal model for nonpalpable implant removal: A pilot study.
Int J Gynaecol Obstet
January 2025
Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Bron, France.
Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.
Front Pharmacol
December 2024
Pharmacy Department, Xiamen Fifth Hospital, Xiamen, Fujian, China.
Background: This study aims to investigate adverse drug reaction signals associated with coagulopathies through data mining using the Adverse Event Reporting System (FAERS) of the US Food and Drug Administration. Prompt identification of high-risk drugs provides a valuable basis for enhancing clinical drug safety.
Methods: The adverse event reports related to coagulopathies from Q1 2004 to Q2 2024 were extracted from the ASCII data packages in FAERS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!